Company intelligence / Profile preview

Axxam

Bresso, Lombardy, Italyaxxam.com ↗

Ownership: Private
Employees: ~125
Development stage: Other

Overview

Axxam does not develop its own therapeutics but provides integrated early drug discovery services—including assay development, high-throughput screening using large compound libraries (>450k compounds), hit-to-lead optimization—for pharmaceutical/biotech companies globally. Their technologies enable identification of bioactive molecules across diverse target classes and therapeutic areas. No clinical results are available since they do not sponsor clinical programs.

Therapeutic areas: Other
Modalities: Small moleculeBiologic (via cell-based and iPSC assays)RNA therapy (platform expertise in RNA biology)Peptides (compound collections include peptides)
Industry: Drug Discovery Services

Partnerships

Momentum Biotechnologies

Beyond the preview

Go deeper on Axxam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axxam.

Explore the full profile